---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-005393"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2024-09-30T23:59:59+00:00"
generated_at: "2026-05-31T01:01:31.789750+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioCryst awarded up to $69M HHS contract for RAPIVAB supply to Strategic National Stockpile

## Summary
- Contract covers up to 95,625 doses of RAPIVAB over five years for influenza treatment.
- First ordering period executed at $13.9M for 19,125 doses to be supplied by Sept 2025.
- Awarded by HHS ASPR; four optional 12-month ordering periods remain.
- Prior CDC contract of $34.7M for up to 50,000 doses concluded in 2022.

## SEC filing metadata
- accession: 0001171843-24-005393
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2024-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184324005393/0001171843-24-005393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184324005393/f8k_093024.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-005393
- JSON: https://secwatch.observer/filing/0001171843-24-005393.json
- Plain text: https://secwatch.observer/filing/0001171843-24-005393.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.